For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and the formulated version represents a genuine change. These groundbreaking therapies protect the transthyretin protein, slowing its harmful build-up and reducing the severity of the illness. Patients are now seeing benefit